Genetic variants associated with warfarin dose in African-American individuals: A genome-wide association study

The Lancet

Volumn 382, Issue 9894, 2013, Pages 790-796

  Perera, Minoli A ^a   Cavallari, Larisa H ^b   Limdi, Nita A ^c   Gamazon, Eric R ^a   Konkashbaev, Anuar ^a   Daneshjou, Roxana ^e   Pluzhnikov, Anna ^a   Crawford, Dana C ^g   Wang, Jelai ^d   Liu, Nianjun ^d   Tatonetti, Nicholas ^e   Bourgeois, Stephane ^h   Takahashi, Harumi ⁱ   Bradford, Yukiko ^g   Burkley, Benjamin M ^j   Desnick, Robert J ^k   Halperin, Jonathan L ^k   Khalifa, Sherief I ^l   Langaee, Taimour Y ^j   Lubitz, Steven A ^m   Nutescu, Edith A ^b   Oetjens, Matthew ^g   Shahin, Mohamed H ^j   Patel, Shitalben R ^b   Sagreiya, Hersh ^e   Tector, Matthew ⁿ   Weck, Karen E ^o   Rieder, Mark J ^q   Scott, Stuart A ^k   Wu, Alan H B ^r   Burmester, James K ^s   Wadelius, Mia ^t   Deloukas, Panos ^h   Wagner, Michael J ^p   Mushiroda, Taisei ^u   Kubo, Michiaki ^u   Roden, Dan M ^g   Cox, Nancy J ^a   Altman, Russ B ^e   Klein, Teri E ^f   Nakamura, Yusuke ^u   Johnson, Julie A ^j   more..

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c The University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e Stanford University   (United States)

^f STANFORD UNIVERSITY   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

ⁱ MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^j UNIVERSITY OF FLORIDA   (United States)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^l Aurora St Luke's Medical Center ^*  (Qatar)

^m MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁿ ST LUKE S MEDICAL CENTER   (United States)

^o UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF NORTH CAROLINA   (United States)

^q UNIVERSITY OF WASHINGTON   (United States)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s MARSHFIELD CLINIC   (United States)

^t UPPSALA UNIVERSITY   (Sweden)

^u RIKEN   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; CYTOCHROME P450 2C9; PROTEIN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

ADULT; AFRICAN AMERICAN; ALLELE; ANTICOAGULANT THERAPY; ARTICLE; CHROMOSOME 10; COHORT ANALYSIS; DRUG DOSE REDUCTION; FEMALE; GENE CLUSTER; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84883135237     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60681-9     Document Type: Article

References (33)

1. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012; 5: 615-21 .
2. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365: 2002-12 .
3. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-26 .
4. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-96 .
5. Limdi NA, Arnett DK, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 2008; 9: 511-26 .
6. Ferder N, Eby CS, Deych E, et al. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost 2010; 8: 95-100 .
7. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-93 .
8. Gage B, Eby C, Johnson J, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84: 326-31 .
9. Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112: 1022-27 .
10. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009; 5: e1000433 .
11. Limdi NA, Beasley TM, Crowley MR, et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 2008; 9: 1445-58 .
12. Cha PC, Mushiroda T, Takahashi A, et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet 2011; 19: 4735-44 .
13. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-64 .
14. Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115: 3827-34 .
15. Tishkoff SA, Dietzsch E, Speed W, et al. Global patterns of linkage disequilibrium at the CD4 locus and modern human origins. Science 1996; 271: 1380-87 .
16. Liu Y, Jeong H, Takahashi H, et al. Decreased warfarin clearance associated with the CYP2C9 R150H (8) polymorphism. Clin Pharmacol Ther 2012; 91: 660-65 .
17. Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998; 63: 519-28 .
18. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 2010; 34: 816-34 .
19. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-09 .
20. Teichert M, Eijgelsheim M, Rivadeneira F, et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet 2009; 18: 3758-68 .
21. Shahin MH, Khalifa SI, Gong Y, et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics 2011; 21: 130-35.
22. Perera MA, Gamazon E, Cavallari LH, et al. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther 2011; 89: 408-15 .
23. Ramirez AH, Shi Y, Schildcrout JS, et al. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics 2012; 13: 407-18 .
24. Cavallari LH, Perera M, Wadelius M, et al. Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. Pharmacogenet Genomics 2012; 22: 152-58 .
25. Schelleman H, Brensinger CM, Chen J, Finkelman BS, Rieder MJ, Kimmel SE. New genetic variant that might improve warfarin dose prediction in African Americans. Br J Clin Pharmacol 2010; 70: 393-99 .
26. Voora D, Koboldt DC, King CR, et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010; 87: 445-51.
27. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-57 .
28. Gamazon ER, Ziliak D, Im HK, et al. Genetic architecture of microRNA expression: implications for the transcriptome and complex traits. Am J Hum Genet 2012; 90: 1046-63 .
29. Cavallari LH, Langaee TY, Momary KM, et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010; 87: 459-64 .
30. The National Board of Health and Welfare. Lakemedelsstatistik. http://192.137.163.49/sdb/lak/val.aspx (accessed May 10, 2013).
31. Anderson JL, Horne BD, Stevens SM, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 2012; 125: 1997-2005 .
32. French B, Joo J, Geller NL, et al. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 2010; 11: 108 .
33. van Schie RM, Wadelius MI, Kamali F, et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 2009; 10: 1687-95.